Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy
Complement C5 inhibitors bring an increased risk for Neisseria infections. A novel complement C3 inhibitor, pegcetacoplan, was recently approved to treat paroxysmal nocturnal hemoglobinuria, a condition commonly treated with complement C5 inhibitors. We present a case of meningococcal sepsis in a pegcetacoplan-treated patient with aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Authors
- Eira Poikonen
- Pia Kivelä (ORCID: https://orcid.org/0000-0002-0678-2694)
- Anna‐Elina Lehtinen
- Vuokko Nummi (ORCID: https://orcid.org/0000-0002-5134-7288)
- Seppo Meri (ORCID: https://orcid.org/0000-0001-9142-501X)
- Jukka Torvikoski (ORCID: https://orcid.org/0009-0004-3730-4670)
- Maija Toropainen (ORCID: https://orcid.org/0000-0002-6956-8361)
- Nathalie Friberg
- Leo Starck (ORCID: https://orcid.org/0000-0002-1021-5449)
Publication Details
- Journal
- Emerging infectious diseases
- Published
- 2025-02-21
- DOI
- https://doi.org/10.3201/eid3103.241182
- Citations
- 5
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.99